University of Virginia

Skanska has secured an additional $66 million contract with the University of Virginia to construct the Paul and Diane Manning Institute of Biotechnology, bringing advanced translational research capabilities to the Commonwealth.

Ascidian Therapeutics has assembled a distinguished Scientific Advisory Board featuring globally recognized RNA biology experts to guide its RNA exon editing platform development.

The University of Virginia has secured a $9.3 million NIH grant as initial funding for a $30 million clinical trial investigating ketamine's potential in treating status epilepticus, a life-threatening seizure condition.

• The University of Virginia is launching a clinical trial to evaluate an AI-powered "Bolus Priming System with Reinforcement Learning" (BPS_RL) for automated insulin delivery in Type 1 diabetes patients. • The three-week trial will involve 16 adult participants testing the enhanced system, which integrates with existing AIDANET technology including a phone app, Dexcom glucose monitor, and Tandem insulin pump. • The innovative system aims to improve blood sugar control during meals and overnight without requiring user input, potentially reducing the burden of diabetes management.

A systematic review of 14 clinical trials indicates that cannabis-based medicines may effectively treat peripheral neuropathy by reducing neuropathic pain.

A post hoc analysis of the AURIGA trial reveals that adding daratumumab to lenalidomide enhances minimal residual disease (MRD)-negativity conversion rates in multiple myeloma patients post-transplant.